South San Francisco, CA – According to filings with the U.S. Securities and Exchange Commission, Soley Therapeutics is raising $20,000,000.00 in new funding. Sources indicate as part of senior management Chief Financial Officer, Ken Alwyn played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Soley Therapeutics

Soley Therapeutics is a San Francisco-based, privately-held biotechnology company that is combining artificial intelligence with unique proprietary molecular and cellular response detection for discovering and developing new efficacious drugs, using image acquisition-based approaches. We have translated decades of research by Soley’s co-founders on cell-responses to perturbations and resulting information-flow within the cell, into quantifiable high-resolution imaging to identify and accelerate the development of novel therapeutic molecules for complex diseases.

To learn more about Soley Therapeutics, visit http://soleytherapeutics.com/

Contact:
Ken Alwyn, Chief Financial Officer
415-850-9841

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved